Page 62 - Read Online

Page 152 Bibi et al. J Transl Genet Genom 2024;8:119-161 https://dx.doi.org/10.20517/jtgg.2023.50

suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer.
Cancer Immunol Immunother 2014;63:1177-87. DOI PubMed
32. Chi N, Tan Z, Ma K, Bao L, Yun Z. Increased circulating myeloid-derived suppressor cells correlate with cancer stages, interleukin-8
and -6 in prostate cancer. Int J Clin Exp Med 2014;7:3181-92. PubMed PMC
33. Calagua C, Russo J, Sun Y, et al. Expression of PD-L1 in hormone-naïve and Treated prostate cancer patients receiving neoadjuvant
abiraterone acetate plus prednisone and leuprolide. Clin Cancer Res 2017;23:6812-22. DOI
34. Shariat SF, Kim JH, Andrews B, et al. Preoperative plasma levels of transforming growth factor β1 strongly predict clinical outcome
in patients with bladder carcinoma. Cancer 2001;92:2985-92. DOI
+
35. Miller AM, Lundberg K, Ozenci V, et al. CD4 CD25 high T cells are enriched in the tumor and peripheral blood of prostate cancer
patients. J Immunol 2006;177:7398-405. DOI
+
+
36. Yokokawa J, Cereda V, Remondo C, et al. Enhanced functionality of CD4 CD25 high FoxP3 regulatory T cells in the peripheral blood
of patients with prostate cancer. Clin Cancer Res 2008;14:1032-40. DOI
37. Getnet D, Maris CH, Hipkiss EL, et al. Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-
specific CD4 T cells. J Immunol 2009;182:4675-85. DOI PubMed PMC
38. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009;182:4499-506.
DOI PubMed PMC
39. Zlotta AR, Egawa S, Pushkar D, et al. Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and
Asian men. J Natl Cancer Inst 2013;105:1050-8. DOI
40. Whittemore AS, Cirillo PM, Feldman D, Cohn BA. Prostate specific antigen levels in young adulthood predict prostate cancer risk:
results from a cohort of Black and White Americans. J Urol 2005;174:872-6; discussion 876. DOI PubMed
41. Vareki S. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint
inhibitors. J Immunother Cancer 2018;6:157. DOI PubMed PMC
42. Perera MPJ, Thomas PB, Risbridger GP, et al. Chimeric antigen receptor T-Cell therapy in metastatic castrate-resistant prostate
cancer. Cancers 2022;14:503. DOI PubMed PMC
43. Mughees M, Kaushal JB, Sharma G, Wajid S, Batra SK, Siddiqui JA. Chemokines and cytokines: axis and allies in prostate cancer
pathogenesis. Semin Cancer Biol 2022;86:497-512. DOI PubMed PMC
44. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol 2006;90:51-81. DOI PubMed
45. Tien AH, Xu L, Helgason CD. Altered immunity accompanies disease progression in a mouse model of prostate dysplasia. Cancer
Res 2005;65:2947-55. DOI
46. Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res 2017;5:3-8. DOI PubMed PMC
47. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
DOI PubMed PMC
48. Mortezaee K. Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives. Life Sci 2021;277:119627. DOI
PubMed
49. Kozin SV, Kamoun WS, Huang Y, Dawson MR, Jain RK, Duda DG. Recruitment of myeloid but not endothelial precursor cells
facilitates tumor regrowth after local irradiation. Cancer Res 2010;70:5679-85. DOI PubMed PMC
50. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002;3:651-62. DOI PubMed
+
51. Vuk-Pavlović S, Bulur PA, Lin Y, et al. Immunosuppressive CD14 HLA-DR low/- monocytes in prostate cancer. Prostate
2010;70:443-55. DOI PubMed PMC
52. Gustafson MP, Lin Y, League SC, et al. Loss of HLA-DR expression on CD14+cells; A common marker of immunosuppression in
cancer patients. J Immunother 2010;33:869-70. Available from: https://www.researchgate.net/publication/295679244_Loss_of_HLA-
DR_Expression_on_CD14Cells_A_Common_Marker_of_Immunosuppression_in_Cancer_Patients [Last accessed on 12 Apr 2024]
53. Pili R, Häggman M, Stadler WM, et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with
minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol 2011;29:4022-8. DOI
54. Björk P, Björk A, Vogl T, et al. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to
quinoline-3-carboxamides. PLoS Biol 2009;7:e97. DOI PubMed PMC
55. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer
2008;8:618-31. DOI PubMed
56. Thakur A, Vaishampayan U, Lum LG. Immunotherapy and immune evasion in prostate cancer. Cancers 2013;5:569-90. DOI
PubMed PMC
57. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol
2007;25:267-96. DOI PubMed PMC
58. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012;12:237-51.
DOI PubMed PMC
59. Balachandran VP, Cavnar MJ, Zeng S, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through
the inhibition of Ido. Nat Med 2011;17:1094-100. DOI PubMed PMC
60. Ozao-Choy J, Ma G, Kao J, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of
tumor microenvironment for immune-based cancer therapies. Cancer Res 2009;69:2514-22. DOI PubMed PMC
+
+
61. Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4 CD25 regulatory T cells suppress tumor immunity but are sensitive to
cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004;34:336-44. DOI